Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rightongene Biotechnology Co Days Payable Chart
SHSE:688217 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Shanghai Rightongene Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rightongene Biotechnology Co Days Payable vs Biotechnology Industry
Shanghai Rightongene Biotechnology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rightongene Biotechnology Co (SHSE:688217) has a Days Payable of 140.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Rightongene Biotechnology Co and its competitors. This is 41% above median its historical median of 100.13. Over the past decade, Shanghai Rightongene Biotechnology Co's Days Payable has ranged from 54.86 to 223.98. According to the industry distribution chart, Shanghai Rightongene Biotechnology Co ranks #347 out of 704 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Shanghai Rightongene Biotechnology Co's Days Payable too high?
Shanghai Rightongene Biotechnology Co's current Days Payable of 140.86 is 41% above median its 10-year median of 100.13. Over the past 10 years, this metric has ranged from a low of 54.86 to a high of 223.98. The Biotechnology industry median Days Payable is 112.72. Shanghai Rightongene Biotechnology Co's value of 140.86 is 25% above this industry median. Based on the distribution chart, Shanghai Rightongene Biotechnology Co ranks #347 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Rightongene Biotechnology Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rightongene Biotechnology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Rightongene Biotechnology Co ranks #347 out of 704 companies for Days Payable. This puts Shanghai Rightongene Biotechnology Co in the upper half of its industry. The industry median Days Payable is 112.72. Shanghai Rightongene Biotechnology Co's value of 140.86 is 25% above this benchmark. Historically, Shanghai Rightongene Biotechnology Co's own Days Payable has ranged from 54.86 to 223.98 over the past decade. While the company's 10-year median is 100.13 vs. the industry median of 112.72, Shanghai Rightongene Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Rightongene Biotechnology Co's current Days Payable of 140.86 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Rightongene Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Rightongene Biotechnology Co's current Days Payable is 140.86, which is 41% above median its own 10-year median of 100.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rightongene Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rightongene Biotechnology Co (SHSE:688217) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.00, compared to a current price of ¥24.70 — trading 64.7% above its estimated fair value. The current Days Payable is 140.86, which is 41% above median its 10-year median of 100.13 and 25% above the Biotechnology industry median of 112.72. Shanghai Rightongene Biotechnology Co's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai Rightongene Biotechnology Co (SHSE:688217), the current Days Payable is 140.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rightongene Biotechnology Co (SHSE:688217) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rightongene Biotechnology Co stock appears to be overvalued.
The current stock price of ¥24.70 is trading 64.7% above its estimated GF Value™ of ¥15.00.
GuruFocus considers Shanghai Rightongene Biotechnology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688217:
Days Payable: 140.86 (41% above median its 10-year median of 100.13)
GF Value™: ¥15.00 vs. price of ¥24.70 (64.7% above fair value)
Industry Position: 25% above the Biotechnology median (#347 of 704)
No single metric tells the full story. See the SHSE:688217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rightongene Biotechnology Co Ltd is engaged in the research and development, production, sales, scientific research and testing services of in vitro diagnostic products.
62GF Score
Get the complete analysis for SHSE:688217
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688217 has been successfully added to your 
